The general quality of included trials was low based on the Jadad scale. Moreover, there were critical failures in most of the trials, including lack of an intention-to-treat analysis for 11 of 13 trials.
One of the publications included in this review was available only in abstract form, and another was a difficult-to-access meta-analysis of 20 unpublished trials. These two publications constituted roughly 66% of participants in the review. Neither publication represented studies for which original peer-reviewed data were available.
It is also worth noting that the term “global improvement” is nebulously defined in many, if not all, of the included studies. Importantly, this outcome measure does not appear to include an integration of the adverse effects of cyclobenzaprine into the assessment of overall benefit.
There is a recent high-quality randomized controlled trial that suggests minimal pain-relieving effect of cyclobenzaprine when used in addition to naproxen for patients with acute low back pain. There may be some benefit, although of questionable magnitude, to the use of cyclobenzaprine. There is a high likelihood of adverse effects. Further research is needed to conclusively address this question. The possible benefit of questionable magnitude has led us to rate this topic yellow (unclear benefits).
The original manuscript was published in
Medicine by the Numbers, American Family Physician as part of the partnership between TheNNT.com and AFP.